Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$1.6 million.

  • Beam Therapeutics' Change in Account Payables fell 12700.0% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 62937.18%. This contributed to the annual value of $1.8 million for FY2024, which is 12384.53% up from last year.
  • Latest data reveals that Beam Therapeutics reported Change in Account Payables of -$1.6 million as of Q3 2025, which was down 12700.0% from $2.6 million recorded in Q2 2025.
  • Beam Therapeutics' Change in Account Payables' 5-year high stood at $3.8 million during Q1 2025, with a 5-year trough of -$3.0 million in Q3 2023.
  • Its 5-year average for Change in Account Payables is $119263.2, with a median of -$231000.0 in 2023.
  • As far as peak fluctuations go, Beam Therapeutics' Change in Account Payables skyrocketed by 101288.66% in 2021, and later crashed by 258431.37% in 2023.
  • Beam Therapeutics' Change in Account Payables (Quarter) stood at $2.2 million in 2021, then surged by 34.32% to $2.9 million in 2022, then plummeted by 160.97% to -$1.8 million in 2023, then skyrocketed by 68.89% to -$550000.0 in 2024, then plummeted by 188.91% to -$1.6 million in 2025.
  • Its Change in Account Payables stands at -$1.6 million for Q3 2025, versus $2.6 million for Q2 2025 and $3.8 million for Q1 2025.